Table 1 Baseline characteristics of patients according to clinical T staging
Characteristic | All patients (n = 25) | cT4a (n = 11) | cT4b (n = 14) |
|---|---|---|---|
Age, median (range) | 63 (48–70) | 64 (51–69) | 61 (48–70) |
Gender, n (%) | |||
Female | 6 (24) | 2 (18) | 4 (29) |
Male | 19 (76) | 9 (82) | 10 (71) |
ECOG, n (%) | |||
0 | 14 (56) | 7 (64) | 7 (50) |
1 | 11 (44) | 4 (36) | 7 (50) |
Clinical T staging, n (%) | |||
T4a | 11 (44) | 11 (100) | 0 (0) |
T4b | 14 (56) | 0 (0) | 14 (100) |
Clinical N staging, n (%) | |||
N2 | 3 (12) | 1 (9) | 2 (14) |
N3 | 22 (88) | 10 (91) | 12 (86) |
PD-L1 (CPS), n (%) | |||
≥10 | 1 (4) | 1 (9) | 0 (0) |
5–10 | 1 (4) | 0 (0) | 1 (7) |
1–5 | 1 (4) | 1 (9) | 0 (0) |
<1 | 21 (84) | 9 (82) | 12 (86) |
Unknown | 1 (4) | 0 | 1 (7) |
MMR/MSI, n (%) | |||
dMMR/MSI-H | 4 (16) | 2 (18) | 2 (14) |
pMMR/MSS | 21 (84) | 9 (82) | 12 (86) |
ERBB2 amplification, n (%) | |||
YES | 4 (16) | 1 (9) | 3 (21) |
No | 21 (84) | 10 (91) | 11 (79) |
Signet cells, n (%) | |||
Yes | 9 (36) | 7 (64) | 2 (14) |
No | 16 (64) | 4 (36) | 12 (86) |
Lauren’s classification, n (%) | |||
Diffused | 16 (64) | 7 (64) | 9 (64) |
Intestinal/mixed | 9 (36) | 4 (36) | 5 (36) |
